AAIC 2025 Abstract
Plasma Phosphorylated Tau 217 predicts cognitive and functional deterioration across clinical stages of Alzheimer's disease
By Judit Selma-González, Sara Rubio-Guerra, Jesus Garcia Castro, Show 28 more authorsIgnacio Illán-Gala
Study in peopleBiomarkers
Abstract
Background: Phosphorylated tau at threonine 217 ( p ‐tau217) is a highly specific blood‐based biomarker for Alzheimer's disease (AD) pathology, with high diagnostic accuracy and reproducible cut‐offs across cohorts. However, the prognostic utility of plasma p ‐tau217 has not been assessed across the clinical stages of AD.
